## Jennie G Jacobson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5979509/publications.pdf

Version: 2024-02-01

25 papers 2,076 citations

430874 18 h-index 25 g-index

26 all docs

26 docs citations

times ranked

26

1517 citing authors

#	Article	IF	CITATIONS
1	Fluoxetine for Acute Treatment of Depression in Children and Adolescents: A Placebo-Controlled, Randomized Clinical Trial. Journal of the American Academy of Child and Adolescent Psychiatry, 2002, 41, 1205-1215.	0.5	522
2	A herpes simplex virus ribonucleotide reductase deletion mutant is defective for productive acute and reactivatable latent infections of mice and for replication in mouse cells. Virology, 1989, 173, 276-283.	2.4	296
3	Fluoxetine Treatment for Obsessive-Compulsive Disorder in Children and Adolescents: A Placebo-Controlled Clinical Trial. Journal of the American Academy of Child and Adolescent Psychiatry, 2001, 40, 773-779.	0.5	286
4	VLA-1: a T cell surface antigen which defines a novel late stage of human T cell activation. European Journal of Immunology, $1985$ , $15$ , $502$ - $508$ .	2.9	152
5	Fluoxetine Treatment for Prevention of Relapse of Depression in Children and Adolescents: A Double-Blind, Placebo-Controlled Study. Journal of the American Academy of Child and Adolescent Psychiatry, 2004, 43, 1397-1405.	0.5	137
6	Pharmacokinetics and Pharmacodynamics of High-Dose Human Regular U-500 Insulin Versus Human Regular U-100 Insulin in Healthy Obese Subjects. Diabetes Care, 2011, 34, 2496-2501.	8.6	106
7	Importance of the Herpes Simplex VirusUL24Gene for Productive Ganglionic Infection in Mice. Virology, 1998, 242, 161-169.	2.4	80
8	Low levels of herpes simplex virus thymidine-thymidylate kinase are not limiting for sensitivity to certain antiviral drugs or for latency in a mouse model. Virology, 1989, 168, 221-231.	2.4	76
9	Olanzapine Plasma Concentrations After Treatment With 10, 20, and 40 mg/d in Patients With Schizophrenia. Journal of Clinical Psychopharmacology, 2009, 29, 278-283.	1.4	75
10	Effect of an amber mutation in the herpes simplex virus thymidine kinase gene on polypeptide synthesis and stability. Virology, 1989, 168, 210-220.	2.4	54
11	Service utilization and associated direct costs for bipolar disorder in 2004: An analysis in managed care. Journal of Affective Disorders, 2007, 101, 187-193.	4.1	47
12	Longer Time to Antipsychotic Treatment Discontinuation for Any Cause Is Associated With Better Functional Outcomes for Patients With Schizophrenia, Schizophreniform Disorder, or Schizoaffective Disorder. Journal of Clinical Psychiatry, 2007, 68, 1163-1171.	2.2	47
13	Fluoxetine 40–60 mg versus Fluoxetine 20 mg in the Treatment of Children and Adolescents with a Less-Than-Complete Response to Nine-Week Treatment with Fluoxetine 10–20 mg: APilot Study. Journal of Child and Adolescent Psychopharmacology, 2006, 16, 207-217.	1.3	33
14	Linker Insertion Mutations in the Herpes Simplex Virus Type 1 UL28 Gene: Effects on UL28 Interaction with UL15 and UL33 and Identification of a Second-Site Mutation in the UL15 Gene That Suppresses a Lethal UL28 Mutation. Journal of Virology, 2006, 80, 12312-12323.	3.4	31
15	Early evaluation of patient risk for substantial weight gain during olanzapine treatment for schizophrenia, schizophreniform, or schizoaffective disorder. BMC Psychiatry, 2008, 8, 78.	2.6	25
16	Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women. Psychiatry Research, 2011, 187, 74-79.	3.3	19
17	Assessment of Treatment Algorithms Including Amantadine, Metformin, and Zonisamide for the Prevention of Weight Gain With Olanzapine. Journal of Clinical Psychiatry, 2012, 73, 216-223.	2.2	19
18	Concentrated insulins: History and critical reappraisal. Journal of Diabetes, 2019, 11, 292-300.	1.8	18

#	Article	IF	CITATIONS
19	Predictive Value of Early Changes in Triglycerides and Weight for Longer-Term Changes in Metabolic Measures During Olanzapine, Ziprasidone or Aripiprazole Treatment for Schizophrenia and Schizoaffective Disorder. Journal of Clinical Psychopharmacology, 2010, 30, 656-660.	1.4	17
20	Synergistic effects on ganglionic herpes simplex virus infections by mutations or drugs that inhibit the viral polymerase and thymidine kinase. Virology, 1995, 206, 263-268.	2.4	13
21	Concomitant Oral Antihyperglycemic Agent Use and Associated Treatment Outcomes After Initiation of Insulin Therapy. Endocrine Practice, 2011, 17, 563-567.	2.1	10
22	Number Needed to Treat or Harm Analyses of Olanzapine for Maintenance Treatment of Bipolar Disorder. Journal of Clinical Psychopharmacology, 2009, 29, 520-528.	1.4	6
23	Potential for use of 1,5-anhydroglucitol when initiating insulin therapy in people with type 2 diabetes and suboptimal control with oral antidiabetic drugs. Diabetes Research and Clinical Practice, 2012, 96, e66-e69.	2.8	3
24	FLUOXETINE FOR DEPRESSION RELAPSE PREVENTION. Journal of the American Academy of Child and Adolescent Psychiatry, 2005, 44, 967-968.	0.5	2
25	Listing of metabolic changes in healthy volunteers receiving orally dissolving olanzapine or oral olanzapine: Data from a clinical study that was terminated early. Schizophrenia Research, 2009, 115, 370-371.	2.0	2